Live Feeds
● LIVE Updated 28m ago · 15 sources tracked

Novo Nordisk shares jump 6% after lifting 2026 outlook on obesity-drug demand

Novo Nordisk shares climbed up to 6% following a third-quarter earnings beat and an upward revision to its full-year 2026 financial outlook. The Danish pharmaceutical company reported third-quarter sales of DKK 79,195 million and net income of DKK 16,740 million. Strong global demand for obesity and diabetes treatments, particularly the oral Wegovy pill, drove the positive results. The oral medication exceeded initial expectations by capturing a dominant share of new US obesity drug prescriptions. Management also accelerated the international rollout of the pill across more than 20 countries.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (15)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novo Nordisk shares jumped as much as 6% on Wednesday after raising its 2026 outlook.
  • ✓ The company reported third-quarter 2026 sales of DKK 79,195 million and net income of DKK 16,740 million.
  • ✓ CEO statements and financial results confirmed that the oral Wegovy pill exceeded expectations and drove strong prescription growth.
  • ✓ Novo Nordisk plans meaningful US list price cuts for Wegovy and Ozempic beginning in January 2027.
🛡️ Source Corroboration: 15 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Novo Nordisk raised its full-year 2026 sales and profit guidance for the third time this year following stronger-than-expected third-quarter results.

Live updates

  1. Novo Nordisk Shares Jump 6% After Hikes to 2026 Outlook

    Novo Nordisk shares climbed up to 6% following a third-quarter earnings beat and an upward revision to its full-year 2026 financial outlook. The Danish pharmaceutical company reported third-quarter sales of DKK 79,195 million and net income of DKK 16,740 million. Strong global demand for obesity and diabetes treatments, particularly the oral Wegovy pill, drove the positive results. The oral medication exceeded initial expectations by capturing a dominant share of new US obesity drug prescriptions. Management also accelerated the international rollout of the pill across more than 20 countries.

    Why it matters

    The strong financial performance highlights the fierce race between Novo Nordisk and rival Eli Lilly within the lucrative weight-loss drug sector. Oral Wegovy has become a central product for the company, helping offset revenue headwinds from volume growth balancing against price drops. Management also plans meaningful United States list price cuts for Wegovy and Ozempic starting in January 2027.

    What is confirmed

    • Novo Nordisk shares jumped as much as 6% on Wednesday after raising its 2026 outlook.
    • The company reported third-quarter 2026 sales of DKK 79,195 million and net income of DKK 16,740 million.
    • CEO statements and financial results confirmed that the oral Wegovy pill exceeded expectations and drove strong prescription growth.
    • Novo Nordisk plans meaningful US list price cuts for Wegovy and Ozempic beginning in January 2027.
    • Obesity sales jumped 22% during the third quarter.

    What to watch next

    • Monitor whether Wegovy maintains its high market share and volume growth against rival Eli Lilly.
    • Track the execution of planned US list price cuts for Wegovy and Ozempic in January 2027.
    Sources used for this update (19)
    1. Yahoo Finance — Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%
    2. Yahoo Finance — Novo Nordisk CEO: Wegovy pill 'exceeded our expectations'
    3. CNBC — Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook
    4. Barron's — Novo Nordisk Weight-Loss Pill Sales Soar. One Other Earnings Revelation Boosting the Stock.
    5. Bloomberg.com — Novo Boosts Forecast on Demand for Wegovy Pill, Ozempic
    6. The Economist — No pain, no gain at Novo
    7. www.cnbc.com — Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook
    8. Investor's Business Daily — Novo Surges After Crushing Forecasts On The Back Of Its GLP-1s
    9. finance.yahoo.com — Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%
    10. finance.yahoo.com — Novo Nordisk Raises 2026 Guidance as Obesity Drug Sales Rise ...
    11. coincentral.com — Novo Nordisk (NVO) Stock Rises 6% After Q3 Beat and Higher ...
    12. www.globalbankingandfinance.com — Novo Nordisk Ups Wegovy Pill Outlook Amid Strong Global Demand
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community